SG Americas Securities LLC Sells 47,765 Shares of Medpace Holdings, Inc. $MEDP

SG Americas Securities LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 79.4% during the first quarter, HoldingsChannel.com reports. The firm owned 12,379 shares of the company’s stock after selling 47,765 shares during the quarter. SG Americas Securities LLC’s holdings in Medpace were worth $5,944,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Balboa Wealth Partners boosted its stake in shares of Medpace by 37.5% during the first quarter. Balboa Wealth Partners now owns 825 shares of the company’s stock valued at $396,000 after purchasing an additional 225 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its stake in Medpace by 247.1% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 51,598 shares of the company’s stock worth $24,777,000 after buying an additional 36,731 shares during the period. Hsbc Holdings PLC purchased a new position in Medpace in the 4th quarter worth about $2,164,000. Corient Private Wealth LLC lifted its holdings in Medpace by 7.0% during the 4th quarter. Corient Private Wealth LLC now owns 1,830 shares of the company’s stock valued at $1,029,000 after buying an additional 120 shares in the last quarter. Finally, Worthington Financial Partners LLC bought a new stake in Medpace during the 4th quarter valued at about $1,082,000. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of research reports. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Barclays dropped their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. BMO Capital Markets reduced their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Royal Bank Of Canada lowered their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Stock Performance

Medpace stock opened at $527.07 on Monday. The business’s 50-day simple moving average is $451.19 and its two-hundred day simple moving average is $496.65. The company has a market cap of $15.05 billion, a PE ratio of 33.13, a PEG ratio of 2.67 and a beta of 1.18. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the business posted $3.67 earnings per share. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.